ZMYND11 and cancer: Considering the pivotal role and clinical relevance of PRMT5 inhibitors in cancer progression,37,38 we explored whether PRMT5 inhibitors could serve as an effective therapeutic strategy for prostate cancer characterized by low ZMYND11 expression.